The National Biologics Facility (NBF) provides key infrastructure maintained under phase-appropriate quality systems to support therapeutic discovery, from screening of antibody libraries and production of high-quality recombinant proteins as small-molecule drug targets, through to novel, engineered biologics, vaccine antigens and diagnostic reagents.

NBF is a network of facilities, platform technologies and subject matter experts focused on the development of your biotherapeutic from discovery through to the scale-up and manufacturing of clinically-relevant material.

Modern Beer Brewery

Biologics & Vaccines

Available expertise

Discovery and Early Protein Development

NBF supports therapeutic discovery and offers expertise in antibody generation and phage display combined with protein and antibody engineering techniques, as well as bioconjugation.

Transient and Stable Expression

NBF has extensive experience across all nodes producing a wide range of proteins in different expressions systems.

Process Development & Characterisation

The NBF team can draw upon hundreds of proteins and decades of combined process development experience to ensure a suitably robust and reliable manufacturing process is established that is phase-appropriate to the endpoint of the biologic being produced.

Clinically Enabled Manufacturing

The NBF has the proven track record of successfully working with our collaborators in developing programs through to Phase I clinical end points.

Contact Us

Do you have a technical problem or a research need? Reach out to us by completing the enquiry form and we will find endeavour to find you the right connection.